ReCode Therapeutics Pitch Deck: All 13 Slides + Teardown

ReCode Therapeutics' Series B deck is a highly technical, data-driven presentation that successfully addresses the primary bottleneck in genetic medicine: delivery. By focusing on their Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform, the company demonstrates a clear path to treating diseases beyond the liver, such as Primary Ciliary Dyskinesia (PCD) and Cystic Fibrosis (CF). The deck excels at providing visual proof of efficacy through bioluminescence imaging in mice, dogs, and non-human primates. While it lacks a traditional team slide or detailed financial breakdown in t…

Key takeaways

• The deck highlights a $280M total raised to date, signaling strong existing investor backing on slide 3.
• ReCode positions its SORT LNP platform as the solution to 'traditional LNP constraints,' specifically enabling extra-hepatic delivery on slide 5.
• The technology is shown to be modular, capable of carrying mRNA, siRNA, and gene editing payloads without size limitations as noted on slide 5.
• Visual evidence of organ selectivity is provided through a 5,000+ SORT LNP library that targets the lung, spleen, and liver on slide 7.
• Cross-species validation is a core pillar, with data shown for mice, dogs, and non-human primates (Cyno) on slide 9.
• The company sets clear near-term milestones with IND filings for PCD in Q4 2022 and CF in Q2 2023 on slide 11.
• The pipeline demonstrates a strategic expansion from lung-focused inhaled delivery to IV and intrathecal delivery for CNS targets on slide 11.
• The deck omits a dedicated team slide, though it mentions a 'strong leadership team' in the summary on slide 3.

Frequently asked questions

What is the primary technological advantage ReCode claims?

ReCode claims their Selective Organ Targeting (SORT) LNP platform overcomes the 'liver-only' limitation of traditional lipid nanoparticles. By adding a 5th SORT lipid, they can predictably engineer delivery to specific organs like the lungs and spleen, which is a significant hurdle for current mRNA and gene editing therapies.

How does ReCode prove their technology works across different animals?

Slide 9 provides bioluminescence imaging showing luciferase expression specifically in the lungs of mice, dogs, and non-human primates (NHPs) following an IV bolus. This cross-species data is critical for biotech investors to de-risk the transition from lab models to human clinical trials.

What are the immediate clinical milestones mentioned in the deck?

The deck identifies two major near-term catalysts: an Investigational New Drug (IND) filing for Primary Ciliary Dyskinesia (PCD) in Q4 2022 and an IND filing for Cystic Fibrosis (CF) in Q2 2023. These milestones provide a clear timeline for the company's transition to a clinical-stage entity.

What types of genetic payloads can the SORT platform carry?

According to slide 5, the platform is 'modular' and can deliver diverse payloads without size constraints. Specifically, it lists mRNA, siRNA, gene editing tools, and mixed payloads, suggesting the platform has utility across a wide range of therapeutic modalities.

Is there information about the management team in this deck?

Slide 3 mentions a 'strong leadership team with rare disease development experience,' but the deck lacks a dedicated slide with names, photos, or specific bios. In a Series B round, this information is usually handled in the confidential data room or via supplemental materials.

ReCode Therapeutics pitch deck: the facts

Company

ReCode Therapeutics

Year

2023

Stage

Series B

Slides

13

Sector

Biotech

Deck type

Financing Round

Outcome

$120M Raised

Headquarters

N. America

ReCode Therapeutics pitch deck PDF

The full ReCode Therapeutics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the ReCode Therapeutics pitch deck was used for

This deck is ReCode Therapeutics’ 13‑slide investor presentation used for the **$120M Series B extension** announced June 29, 2022, which brought its total Series B financing to $200M.[2][3][5] The company is a genetic medicines biotech focused on tissue‑specific delivery of mRNA and gene correction therapies via its proprietary **Selective Organ Targeting (SORT) LNP** platform.[3][4][5] The deck was used amid a challenging biotech funding environment to persuade investors to extend an existing $80M Series B raised in October 2021.[2][3][13] Proceeds from this Series B were earmarked to diversify ReCode’s pipeline into CNS, liver, and oncology indications and to advance lead programs for primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into the clinic.[5][15]

Business model: ReCode Therapeutics is a clinical-stage genetic medicines company developing mRNA and gene correction therapeutics enabled by its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, which aims to deliver genetic medicines to specific organs, tissues, and cells implicated in disease.[1][4][5]

Investors

Leaps by Bayer[2][5][6][13][14], AyurMaya (affiliate of Matrix Capital Management)[2][5][6][13][14], Amgen Ventures[2][5][6][13][14], Pfizer Ventures[2][5][13][14], Sanofi Ventures[2][5][13][14], EcoR1 Capital[2][5][13][14], Osage University Partners[6], Colt Ventures[14]

Founded

2012[9]

Headquarters

Menlo Park, California and Dallas, Texas[5][9]

Industry

Biopharmaceuticals / Biotechnology / Genetic medicines[5][9]

Round: Series B extension (part of overall Series B financing)[2][5][6][13]

Year: 2022[2][5][13]

Raised: $120M in the Series B extension round associated with this 13‑slide pitch deck, bringing total Series B funding to $200M at that time.[2][3][5]

Lead investor: Leaps by Bayer and AyurMaya co‑led the $120M Series B extension; Pfizer Ventures co‑led the initial $80M Series B.[2][5][6][13][14]

Total funding: At least $260M raised in Series B financing (initial $80M announced October 2021 plus $120M June 2022 extension to $200M and a further $60M extension to $260M reported September 2023), with additional non‑dilutive and other financing including more than $29M announced in 2026.[1][2][4][5]

Use of funds as presented: Diversify ReCode’s genetic medicines pipeline into CNS, liver, and oncology indications while advancing its lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis into the clinic, including filing FDA requests to begin human trials.[5][15]

What happened after the ReCode Therapeutics deck

The 13‑slide pitch deck helped ReCode secure a $120M Series B extension in June 2022, increasing its Series B from $80M to $200M to fund diversification of its SORT LNP‑enabled pipeline and advancement of lead PCD and CF programs into the clinic.[2][3][5][15] ReCode subsequently extended the Series B further to $260M in 2023 and continued to raise capital and form collaborations, indicating that t

• October 2021: ReCode announced an initial **$80M Series B** round, co‑led by Pfizer Ventures with participation from San
• June 29, 2022: ReCode closed a **$120M Series B extension** co‑led by Leaps by Bayer and AyurMaya, with Amgen Ventures p
• 2022–2023: The company indicated it would use Series B proceeds to diversify its pipeline into CNS, liver, and oncology
• September 2023: ReCode announced a **final extension of its Series B financing**, raising an additional **$60M** and bri
• August 2026: ReCode reported over **$29M in additional financing** and new CF‑focused collaborations, reinforcing ongoin

What the ReCode Therapeutics deck got right

• Compelling, differentiated platform story around SORT LNP and extrahepatic delivery. The deck centers on ReCode’s proprietary **Selective Organ Targeting (SORT) LNP platform**, which external coverage describes as enabling highly precise, tissue‑specific delivery of genetic medicines and extrahepatic targeting validated by cross‑species data—an unusually strong, platform‑level scientific differentiator for a Series B pitch.[3][4][5][13]
• High‑quality, strategically aligned investor syndicate validated by the deck. The Series B extension was **co‑led by Leaps by Bayer and AyurMaya** with participation from **Amgen Ventures**, and built on an initial Series B backed by **Pfizer Ventures, Sanofi Ventures, EcoR1 Capital**, and others, demonstrating that the pitch deck successfully attracted a high‑quality mix of strategic and financial investors in a challenging biotech market.[2][5][6][13][14]
• Clear linkage between funding, lead programs, and pipeline expansion. Proceeds were clearly tied to **advancing specific lead programs (PCD and CF) into the clinic** and **diversifying the pipeline** into CNS, liver, and oncology indications, showing investors a concrete plan for translating platform capabilities into multiple therapeutic opportunities.[5][13][15]
• Strong academic and translational backing. ReCode’s origins as a **UT Southwestern Medical Center spinout** and positioning as a clinical‑stage company provide institutional and translational credibility that strengthens the scientific claims made in the deck and appeals to investors seeking academically grounded innovation.[6][9]
• Demonstrated fundraising effectiveness and scalability of the story. The ability to secure an oversubscribed $120M extension to an $80M Series B—and later extend the Series B further to $260M—indicates that the deck effectively communicated a scalable vision and instilled sufficient confidence for investors to increase their commitments, suggesting robust narrative and data quality.[1][2][3][5]
• Efficient use of rigorous preclinical data within a concise 13‑slide format. External articles note that the deck uses **cross‑species data to validate extrahepatic delivery**, which is a powerful way to demonstrate platform robustness and translational potential to investors without overwhelming them with excessive slide count (13 slides).[[3]]

What could have been stronger

• Limited visibility into concrete development and commercial milestones in the deck. Public descriptions of the pitch deck emphasize the SORT LNP platform and cross‑species extrahepatic delivery data, but available secondary coverage does not show detailed clinical, regulatory, or commercial traction metrics (e.g., no clear timelines for first‑in‑human trials, partnership economics, or revenue projections), which can make it harder for investors to fully assess near‑term value inflection points based solely on the deck.[3][5][13][15]
• Pipeline prioritization and focus not clearly evidenced from deck coverage. While external articles explain that proceeds would diversify the pipeline into CNS, liver, and oncology indications and advance PCD and CF programs, the pitch‑deck coverage does not reveal how the company prioritized these programs, their relative readiness, or risk‑adjusted resource allocation, leaving potential ambiguity around focus and execution strategy as presented in the deck.[3][5][15]
• Insufficiently explicit competitive landscape and differentiation analysis in public view. The deck evidently focuses on ReCode’s SORT LNP delivery advantages and extrahepatic targeting, but publicly available descriptions do not detail systematic competitive comparisons versus other LNP or non‑viral delivery platforms (e.g., quantitative head‑to‑head data or IP positioning), which may weaken the argument for why ReCode’s approach is defensible in the long term.[3][4][5][13]
• Lack of explicit financial roadmap and capital‑efficiency narrative. Coverage of the pitch deck and financing does not disclose any clear long‑term financial plan (e.g., runway duration, expected cash burn by program, or milestones tied to tranche releases), which can be a gap for investors seeking rigorous capital‑efficiency and financial discipline signals in an oversubscribed round.[2][3][5][15]

How an investor would read this deck

What draws attention

• Ability of the SORT LNP platform to reliably deliver genetic medicines to extrahepatic tissues across species, including the strength, breadth, and reproducibility of the underlying in vivo data the deck highlights.[3][4][5][13]
• Progress and de‑risking of lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis, especially preclinical package robustness, regulatory interactions, and timelines to first‑in‑human studies, given that Series B proceeds were earmarked for these milestones.[5][13][15]
• Quality and strategic fit of the investor syndicate—Leaps by Bayer, AyurMaya/Matrix Capital Management, Pfizer Ventures, Sanofi Ventures, Amgen Ventures, EcoR1 Capital, and others—indicating validation by both strategic and financial investors and potential for downstream partnerships.[2][5][6][13][
• ReCode’s origins as a UT Southwestern Medical Center spinout and the depth of its academic and translational backing, relevant IP, and licensing arrangements supporting long‑term defensibility.[6][9]
• Management team’s ability to execute in a challenging biotech funding environment, evidenced by securing an oversubscribed Series B extension and later additional financings, suggesting resilience and investor confidence.[2][3][4][5]

Risks that stand out

• Technological risk that the SORT LNP platform may not consistently achieve the claimed tissue‑specific and extrahepatic delivery in humans, even if preclinical cross‑species data are promising, which would directly impact the value of the platform‑centric investment thesis.[3][4][5][13]
• Clinical development risk for the lead PCD and CF programs—rare disease biology, delivery challenges in lung and airway tissues, and regulatory uncertainties could lead to delays, unforeseen safety signals, or efficacy shortfalls despite encouraging preclinical results.[5][13][15]
• Competitive risk from other genetic medicine and LNP delivery companies (including those backed by large pharmas) pursuing extrahepatic targeting and mRNA/gene‑editing therapeutics, which may erode differentiation if ReCode’s advantages are incremental rather than step‑change.[4][5][13]
• Execution risk related to advancing a diversified pipeline across CNS, liver, oncology, and pulmonary indications simultaneously; overextension could strain resources and focus, particularly if multiple programs hit clinical inflection points at once.[5][15]
• Financing and market‑cycle risk: the Series B was raised during a biotech downturn, and future capital needs for late‑stage trials and commercialization could be challenged by macro conditions despite strong early investor support.[2][3][9][15]

Questions this deck invites

• What specific in vivo and cross‑species datasets underpin the SORT LNP platform’s extrahepatic delivery claims highlighted in the pitch deck, and how do these compare quantitatively to other leading LNP or non‑viral delivery approaches?[3][
• What are the detailed development plans, timelines, and regulatory strategies for the lead PCD and CF programs funded by the Series B, including expected clinical entry dates, primary endpoints, and go/no‑go criteria?[5][13][15]
• How is capital from the $200M Series B allocated across platforms and indications (PCD, CF, CNS, liver, oncology), and what concrete value‑inflection milestones are expected within the funded runway?[5][15]
• What is ReCode’s IP position around SORT LNP (patent families, freedom‑to‑operate, and key expiries), and how does it prevent competitors from replicating tissue‑specific targeting capabilities?[4][5][9]
• How have subsequent financings and strategic collaborations (such as new CF Foundation funding and a gene‑editing collaboration) validated or evolved the business plan presented in the original Series B pitch deck, and what new data have em

What founders can take from the ReCode Therapeutics deck

• A clearly articulated and differentiated **platform story**—in this case, tissue‑specific SORT LNP delivery with cross‑species extrahepatic data—can attract substantial Series B capital even in a difficult market, provided investors see a credible path from technology to multiple high‑value indicati
• Demonstrating how new capital will **translate into specific pipeline expansions and clinical milestones** (PCD and CF clinical advancement, diversification into CNS, liver, and oncology) helps investors connect funds to value‑creation steps rather than abstract R&D.[5][13][15]
• Building a syndicate that combines **strategic corporate investors** (Pfizer Ventures, Sanofi Ventures, Leaps by Bayer, Amgen Ventures) with specialist financial VCs (EcoR1 Capital, Matrix/AyurMaya, Osage University Partners) can both validate the science and create future partnering optionality.[2]
• Positioning the company as a **spinout from a leading academic institution** (UT Southwestern Medical Center) with deep scientific roots and IP backing can enhance credibility when pitching complex genetic‑medicine platforms.[6][9]
• Using an **extended Series B** structure (initial $80M followed by $120M extension) allows a company to capitalize on emerging data and investor interest, effectively upsizing a round as milestones are met and market receptivity improves.[2][5][6][13]
• Follow‑on financings and collaborations (e.g., additional Series B extension to $260M and CF Foundation/gene‑editing deals) can retroactively validate the strategy outlined in the deck, underscoring the importance of presenting a roadmap that remains compelling to later investors.[1][4][5]

ReCode Therapeutics pitch deck: common questions

What does ReCode Therapeutics do?

ReCode Therapeutics is a clinical‑stage genetic medicines company developing mRNA and gene correction therapeutics using its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver genetic medicines directly to specific organs, tissues, and cells implicated in disease.[4][5] Its lead programs target primary ciliary dyskinesia (PCD) and cystic fibrosis (CF), and the company is expanding into CNS, liver, and oncology indications.[5][15]

Which fundraise was ReCode’s 13‑slide pitch deck used for, and how much was raised?

The 13‑slide pitch deck was used for ReCode’s **$120M Series B extension** financing announced June 29, 2022.[2][3][5] That financing, co‑led by Leaps by Bayer and AyurMaya (an affiliate of Matrix Capital Management) with participation from Amgen Ventures and others, increased the company’s total Series B funding from $80M to $200M.[2][5][6][13]

Who invested in ReCode Therapeutics’ Series B and its extension?

Key investors in the $120M Series B extension included **Leaps by Bayer** and **AyurMaya**, which co‑led the round, with **Amgen Ventures** participating.[2][5][6][13] The $80M initial Series B announced October 2021 included investors such as Pfizer Ventures, EcoR1 Capital, and Sanofi Ventures, among others.[2][5][13][14]

What was the Series B funding (and extension) intended to be used for?

According to ReCode and multiple reports, the company planned to use the Series B capital to **diversify its pipeline** into CNS, liver, and oncology indications and to **advance its lead mRNA programs for PCD and CF into the clinic**, including filing FDA requests to start human trials.[5][15]

What is ReCode’s Selective Organ Targeting (SORT) LNP platform and how does it relate to the pitch deck?

ReCode’s SORT LNP platform is described as a proprietary delivery technology that enables **highly precise, tissue‑specific delivery of genetic medicines**, supporting extrahepatic (beyond the liver) targeting and allowing delivery of different cargo types including mRNA, siRNA, and DNA.[4][5][15] The Business Insider article on the pitch deck notes that the deck emphasized cross‑species data validating extrahepatic delivery, although the underlying slide data are not fully visible in OCR.[3]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• ReCode Therapeutics Announces Closing of Extension to Series B ...
• ReCode breaks the mold with $120M financing, Big Pharma backing
• ReCode's 13-Slide Pitch Deck for a $120 Million Series B Raise
• ReCode Therapeutics Announces New Funding from the ...
• ReCode Therapeutics to Expand Next-Generation Delivery Platform ...
• ReCode registers $120m series B extension
• ReCode Therapeutics (Biopharma, Biotechnology) - Bounce Watch
• ReCode Therapeutics - Raised $342M Funding from 20 investors - Tracxn

Related fundraising guides (24)

• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• Hone Pitch Deck Teardown: Defining the 'Missing Middle' of Corporate Learning
• EcoVadis Pitch Deck Teardown: A Masterclass in Growth-Stage Market Dominance
• Bloom Community Pitch Deck Teardown: Scaling Niche Social Networks Through Event Flywheels
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Impossible Kicks Pitch Deck Teardown: Scaling High-Volume Physical Retail for Sneaker Resale
• Everphone Pitch Deck Teardown: A $200M Masterclass in Unit Economics and Circularity
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Cellarity Pitch Deck Teardown: A $121M Series C Masterclass in Platform-First Biotech
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• Florence Pitch Deck Teardown: Scaling a Healthcare Staffing Marketplace to £9bn Market Potential
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• Green Li-ion Pitch Deck Teardown: A Masterclass in Supply Chain Disruption for Battery Recycling
• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• api.video Pitch Deck Teardown: A Developer-First Approach to $12M Series A
• RegioHelden Pitch Deck Teardown: A Masterclass in Local Marketing Unit Economics
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility

This deck's categories (1)

• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2023 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $50M to $250M

Browse companies alphabetically (1)

• Pitch decks from companies starting with R

Decks in the same category (12)

• MySQL 2003 Series B Pitch Deck Breakdown
• Oscar Health Pitch Deck Breakdown
• LinkedIn 2004 Pitch Deck Breakdown: How Networks Became the Next Big Thing
• DoggyHut Pitch Deck Breakdown: The Perfect Series A Deck For A Company That Does Not Exist
• Monzo Pitch Deck Breakdown: Building the Bank of the Future
• Pendo Series B Pitch Deck Breakdown
• Taster Pitch Deck Breakdown: Scaling Digital Restaurant Brands via a Licensing Model
• Zio Studios Pitch Deck Breakdown: A Transmedia Pivot from Services to IP
• Hadean Pitch Deck Breakdown: Proving Technical Scale Through Enterprise Case Studies
• Now Pitch Deck Breakdown: A $29M Series A Built on Municipal Bond Securitization
• Hangry Pitch Deck Breakdown: Scaling Multi-Brand Virtual Restaurants in Indonesia
• Seedtag Pitch Deck Breakdown: Leveraging the Post-Cookie Era with Contextual AI

More pitch deck teardowns (16)

• Reality Loops Pitch Deck Teardown: A Hyper-Local XR Marketplace Seeking Micro-Funding
• Real Matters Pitch Deck Teardown: Scaling a Network-Effect PropTech for a $16B Market
• Realtime Robotics Pitch Deck Breakdown: Solving the $350k Robot Lifetime Cost Problem
• Realtime Robotics Pitch Deck Teardown: Solving the $350k Robot Lifetime Cost Problem
• RealtyShares Pitch Deck Breakdown: A 6-Slide Masterclass in Marketplace Traction
• Rebel Girls Pitch Deck Breakdown: Scaling a Multi-Platform Media Empire for Gen Alpha
• Recast Pitch Deck Teardown: Leveraging the Death of Digital Tracking for a $3.4M Seed
• Recess Pitch Deck Teardown: How a Marketplace for Experiential Marketing Raised $5M
• Recogni Pitch Deck Breakdown: Solving the Power-Performance Wall for Level 3+ Autonomy
• Recraft Pitch Deck Breakdown: A Masterclass in Product-Led Traction for Generative AI
• RecruitBot Pitch Deck Teardown: A $8.2M Seed Round Driven by Product-Led Growth Strategy
• Recruiter.com Pitch Deck Teardown: A Multi-Tiered Marketplace for the Great Rehire
• Recurrence Pitch Deck Teardown: High-Velocity Sales in the Academic Case Study Market
• Redakt CMS Pitch Deck Teardown: A Technical Bet on the .NET Core Ecosystem
• Redbox SPAC Pitch Deck Breakdown: Pivoting a Legacy Kiosk Giant to Digital Streaming
• Reddit IPO Pitch Deck Breakdown: How a Meme-Heavy Deck Secured a $6.4B Valuation

Recently published pitch deck teardowns (12)

• Genie AI Pitch Deck Teardown: A Masterclass in Technical Credibility and Growth Velocity
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Golpo AI Pitch Deck Teardown: A 7-Slide Masterclass in Technical Pedigree and Velocity
• Koi Pitch Deck Teardown: A $38M Series A Built on Social Proof and Market Evolution
• Kora Pitch Deck Teardown: A $2.6M Seed Round to Compete with the Tesla Powerwall
• WageFi Pitch Deck Teardown: A Lean 10-Slide Approach to Earned Wage Access
• Voxel Pitch Deck Teardown: A Masterclass in Visualizing Invisible Industrial Risk
• VO/D Pitch Deck Teardown: A Systematic $5M Blueprint for Celebrity-Led CPG Ventures
• Well Dot Inc. Pitch Deck Teardown: A $40M Series A Masterclass in Consumer-Grade Healthcare AI
• Worldr Pitch Deck Teardown: A Masterclass in Enterprise Security Social Proof
• AdVolve Media Pitch Deck Teardown: A Hardware-Enabled Ad Network for Captive Audiences
• ANDi Games LTD Pitch Deck Teardown: A B2B2C Play for Mobile Discovery

Fundraising library · Pitch deck examples · Investor directory · Founder database